Esperion (ESPR) announced that it has entered into a settlement agreement with Dr. Reddy’s Laboratories (RDY) and its affiliate Dr. Reddy’s Laboratories. This agreement resolves the patent litigation brought by Esperion against Dr. Reddy’s Laboratories in response to Dr. Reddy’s Laboratories’ Abbreviated New Drug Application, ANDA, seeking approval to market a generic version of each of NEXLETOL and NEXLIZET prior to the expiration of the applicable patents. Pursuant to the agreement, Dr. Reddy’s Laboratories has agreed not to market a generic version of either NEXLETOL or NEXLIZET in the United States prior to April 19, 2040, unless certain limited circumstances customarily included in these types of agreements occur.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESPR:
- Esperion management to meet with Cantor Fitzgerald
- Esperion price target raised to $9 from $7 at Cantor Fitzgerald
- Esperion’s US Market Stagnation Overshadows Japanese Approval, Justifying Sell Rating
- Esperion’s Strategic Milestone: Nexletol Approval in Japan Boosts Financial Outlook with $120 Million Potential
- Esperion’s Strategic Advancements: Regulatory Approval and Market Expansion Boost